The New Game Changer for Weight Loss aka Skinny Me Injection

Semaglutide (the generic medication of Ozempic/Wegovy) FDA approved Weight Loss Medication known as "The Game Changer" for weight loss by medical professionals.  Join our program which includes the generic medication Semaglutide with B12 and unlimited access to our team.

How it works:  Decreases your appetite which lowers your total daily caloric intake and makes you feel full.  Weekly self-administered injections.

 

Why we are different:

 

-You will receive Semaglutide and Vitamin B12 within your monthly supply

-We have medical profession staff

-We offer concierge services with access to our team

-No shortages since we offer the generic medication of Ozempic/Wegovy

 

How To Start:  Easy as 1,2,3!

1. Complete the registration for weight loss below

 
2. After completing the form, our team will discuss and answer any questions you have about the medications process of getting started, and pricing of our program
If approved by our program, you will be required to make payment and your package will be on the way.  Please remember taxes and shipping has to be included

3. You will recieve a confirmation text with the decision

[Semaglutide for Weight Loss Policy]
Policy Statement:

This policy outlines the guidelines for the use of Semaglutide, a glucagon-like peptide-1 (GLP-1)receptor agonist, for weight loss in patients with obesity or overweight individuals who have at least one weight-related comorbidity (e.g., type 2 diabetes, high blood pressure, high cholesterol). The purpose of this policy is to ensure the safe and appropriate use of Semaglutide to achieve optimal outcomes while minimizing potential risks.

Policy Details:
1. Indications for Semaglutide Use: Semaglutide may be prescribed for adults with a body mass index (BMI) of 27 kg/m² or higher and who have at least one weight-related comorbidity, or adults with a BMI of 30 kg/m² or higher. Patients should also have attempted lifestyle modifications, such as dietary changes and increased physical activity, before starting Semaglutide treatment.

2. Pre-treatment Assessment: Before initiating Semaglutide for weight loss, patients should undergo a comprehensive medical assessment, including a thorough medical history, physical examination, and relevant blood work. The blood work should include fasting blood glucose levels, liver function tests, kidney function tests, lipid profile, and HbA1c if applicable.

3. Contraindications: Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). It should not be used in patients with a known
hypersensitivity to Semaglutide or any of its components.

4. Monitoring and Follow-up: Regular follow-up visits should be scheduled to monitor the patients progress and assess the medications safety and efficacy. Patients should undergo routine blood work and vital sign measurements as deemed necessary by the treating healthcare provider.

5. Lifestyle Modifications: Semaglutide treatment should be accompanied by ongoing lifestyle modifications, including a reduced-calorie diet and increased physical activity. Patients should receive counseling on healthy eating habits and exercise routines to maximize weight loss outcomes.

6. Adverse Reactions: Patients should be informed about the potential adverse reactions associated with Semaglutide, which may include nausea, vomiting, diarrhea, constipation, and the risk of low blood sugar (hypoglycemia) when used with other diabetes medications. Any unexpected side effects should be promptly reported to the prescribing healthcare provider.

7. Discontinuation: If patients fail to achieve adequate weight loss, experience intolerable side effects, or demonstrate signs of non-compliance, the healthcare provider should reassess the treatments appropriateness and consider alternative weight management strategies.

8. Informed Consent: Before initiating Semaglutide treatment, healthcare providers should obtain informed consent from patients, explaining the purpose, benefits, risks, and potential alternatives to this therapy. Patients should be given ample opportunity to ask questions and clarify any concerns they may have.

9. Confidentiality: Patient health information and records related to Semaglutide
treatment should be handled with strict confidentiality, adhering to all applicable laws and regulations.

10. Policy Review: This policy will be regularly reviewed and updated as needed to reflect current medical guidelines and best practices.
This policy serves as a guideline for healthcare providers prescribing Semaglutide for weight loss, promoting patient safety, and ensuring optimal outcomes in the management of obesity and associated comorbidities.

Semaglutide Medical Consent Form
Patient Name: ________________________ Date of Birth: ________________________
I, the undersigned, hereby acknowledge that I have been informed and educated about the medication Semaglutide for weight loss. I have had the opportunity to ask questions and have received satisfactory answers to my inquiries.
Semaglutide is an injectable medication that is approved by the appropriate regulatory authorities for weight management in adults with obesity or overweight individuals who have at least one weight-related comorbidity (e.g., type 2 diabetes, high blood pressure, high cholesterol). It is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by regulating appetite and promoting feelings of fullness.

I understand that Semaglutide is not a standalone treatment for obesity but should be used in conjunction with a reduced-calorie diet and increased physical activity for optimal results. I acknowledge that the use of this medication may help me achieve weight loss and improve certain weight-related health conditions.
Risks and Side Effects: I have been made aware of the potential risks and side effects associated with Semaglutide. These may include, but are not limited to:

1. Nausea and vomiting
2. Diarrhea
3. Constipation
4. Abdominal pain
5. Low blood sugar (hypoglycemia), particularly when used with other diabetes
medications
6. Pancreatitis (inflammation of the pancreas)
7. Gallbladder disease
8. Dehydration
9. Kidney problems

I understand that it is crucial to promptly report any adverse effects or concerns during the course of my treatment to my healthcare provider.
Benefits: The potential benefits of Semaglutide may include significant weight loss,
improvements in weight-related comorbidities (such as diabetes and hypertension), and an enhanced quality of life. However, individual results may vary.
Alternatives: I have been informed of alternative weight loss treatments and lifestyle modifications that may be suitable for my specific condition. I understand that it is essential to discuss these options further with my healthcare provider to determine the best course of action for my health and well-being.
Confidentiality: I acknowledge that my health information and medical records related to this treatment will be handled with strict confidentiality, following all applicable laws and regulations.

Voluntary Consent: By signing this form, I affirm that I have voluntarily chosen to initiate Semaglutide treatment for weight loss after a thorough discussion with my healthcare provider.

I have been given adequate time to consider the risks and benefits and have had all my questions answered to my satisfaction.

I understand that I have the right to withdraw my consent for this treatment at any time and that the provider will discuss alternative options with me should I decide to discontinue the use of Semaglutide.

I have received a copy of this consent form for my records.
Patient Signature: ________________________ Date: ________________________
Healthcare Provider Signature: ________________________ Date: _______________________

Semaglutide Consent for Blood Work or Refusal for Blood Work
Patient Name: ________________________ Date of Birth: ________________________
I, the undersigned, hereby acknowledge that I have been informed by my healthcare provider about the importance of blood work before and during the course of Semaglutide treatment for weight loss. I understand that blood work is a critical aspect of ensuring safe and effective use of this medication.
1. Consent for Blood Work:
I ,______________________ consent to the necessary blood work as recommended by my healthcare provider before starting Semaglutide treatment. This includes :
 Blood glucose levels
 Liver function tests
 Kidney function tests
 Hemoglobin A1c (HbA1c) if applicable
I understand that regular monitoring of my blood parameters will be required during the course of Semaglutide treatment to ensure its safety and efficacy. I agree to comply with my healthcare providers instructions regarding follow-up blood work and appointments.
Patient Signature: ________________________ Date: ________________________
Healthcare Provider Signature: ________________________ Date: ______________

2. Refuse Blood Work
I, _______________________ Refuse Blood Work:
I acknowledge that my healthcare provider has recommended undergoing blood work before and during Semaglutide treatment to monitor its effects and assess any potential risks. Despite being fully informed about the importance of these tests, I am choosing to decline blood work at this time.
I understand that refusing blood work may compromise the safety and effectiveness of Semaglutide treatment. I accept full responsibility for any consequences that may arise from my decision to decline blood work and I release my healthcare provider and the medical facility from any liability related to this refusal.

Patient Signature: ________________________ Date: ________________________
Healthcare Provider Signature: ________________________ Date: ______________
3. I,____________________________ had blood work drawn within the past 6months and
will provide a copy to the clinic for records.
Patient Signature: ________________________ Date: ________________________
Healthcare Provider Signature: ________________________ Date: ______________